Gh Research Plc stock is traded at $19.93, with a volume of 297,748. It is down -1.73% in the last 24 hours and down -13.12% over the past month. GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
Previous Close:
$20.28
Open:
$20.73
24h Volume:
297,748
Relative Volume:
0.78
Market Cap:
$1.37B
Revenue:
-
Net Income/Loss:
-$48.26M
P/E Ratio:
-
EPS:
-$0.7899
Net Cash Flow:
-$45.04M
1W Performance:
-3.77%
1M Performance:
-13.12%
6M Performance:
-8.11%
1Y Performance:
+47.63%
1-Day Range:
$18.29$20.87
1-Week Range:
$18.29$21.40
52-Week Range:
$12.04$31.44
Gh Research Plc Stock (GHRS) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS